SGLT2 inhibitors can work within two hours, researchers claim
SGLT2 inhibitors lower blood glucose from just two hours after the first dose, new research has found.
The study, produced by Japanese researchers and published in Diabetology and Metabolic Syndrome, also found the class of drug used to treat type 2 diabetes can improve blood glucose variation within a week of treatment getting underway.
Furthermore, SGLT2 inhibitors did not alter the incidence of hypoglycemic episodes at week 1, suggesting that SGLT2 protects against severe hypoglycaemia by inhibiting urinary glucose excretion.
The study subjects were 24 patients with type 2 diabetes whose blood glucose dynamics were evaluated with continuous glucose monitoring for one week before and after initiation of SGLT2 inhibitor therapy.
Blood glucose dynamics were examined on days −1, 0 (treatment commencement day), 3, and 7 by evaluating different continuous glucose monitoring parameters and blood glucose before each meal. Blood glucose levels were also recorded one and two hours after each meal and daily urinary glucose levels were determined.
Researchers said: “Only a few studies have evaluated blood glucose dynamics in the early period after administration. The present retrospective study was designed to determine the immediate effects of SGLT2 inhibitors on blood glucose dynamics.
“Inhibitors of sodium-glucose co-transporter 2 (SGLT2) have immediate glucose-lowering effects by promoting urinary glucose excretion, without altering insulin level.”
To view the study, click here.